Document is current
Any future updates will be listed below
-
Authors
Chong, Catherine D. https://orcid.org/0000-0002-9035-8748
Zhang, Jianwei
Li, Jing
Wu, Teresa
Dumkrieger, Gina
Nikolova, Simona
Ross, Katherine
Stegmann, Gabriela
Liss, Julie
Schwedt, Todd J.
Jayasuriya, Suren
Berisha, Visar
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (1R61NS113315-01)
- License Information
-
More Information
Article History
Received: 8 June 2021
Accepted: 12 July 2021
First Online: 23 July 2021
Declarations
:
: This study received approval from the Mayo Clinic Institutional Review Board and the Phoenix VA Healthcare System Institutional Review Board. All subjects completed written informed consent prior to study participation.
: Not applicable.
: Simona Nikolova, Katherine Ross, Suren Jayasuriya, Jianwei Zhang, Teresa Wu and Jing Li, declare no competing interests. Gina Dumkrieger declares research funding from Amgen. Catherine Chong has received research funding from Amgen, the U.S. Department of Defense, and the National Institutes of Health. Julie Liss is co-founder and has equity in Aural Analytics, Inc. Gabriella Stegmann is an employee at Aural Analytics, Inc. Within the last 12 months, Todd Schwedt has served as a consultant for Abbvie, Allergan, Biohaven, Click Therapeutics, Eli Lilly, Equinox, Lundbeck, Novartis, and Tonix. He has stock options in Aural Analytics and Nocira. He has received royalties from UpToDate. He has received research funding from: Amgen, American Migraine Foundation, Henry Jackson Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, and U.S. Department of Defense. He serves on the Board of Directors for the American Headache Society and the International Headache Society. Visar Berisha is co-founder and has equity in Aural Analytics, Inc.
